Similar articles for PMID: 28906051

Year	Number of Results
1995	1
1998	2
2002	1
2003	1
2005	3
2006	4
2007	3
2008	6
2009	3
2010	3
2011	2
2012	2
2013	5
2014	11
2015	18
2016	26
2017	54
2018	73
2019	68
2020	59
2021	38
2022	53
2023	10
2024	0

1

Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.

Schwensen JF, Clemmensen A, Sand C, Gniadecki R, Skov L, Zachariae C, Iversen L, Rasmussen M, Thomsen SF. Schwensen JF, et al. Dermatol Ther. 2017 Nov;30(6). doi: 10.1111/dth.12550. Epub 2017 Sep 14. Dermatol Ther. 2017. PMID: 28906051

2

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.

Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C. Rich P, et al. Br J Dermatol. 2013 Feb;168(2):402-11. doi: 10.1111/bjd.12112. Br J Dermatol. 2013. PMID: 23362969 Clinical Trial.

3

Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study.

Körber A, Thaçi D, von Kiedrowski R, Bachhuber T, Melzer N, Kasparek T, Kraehn-Senftleben G, Amon U, Augustin M. Körber A, et al. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):411-419. doi: 10.1111/jdv.14604. Epub 2017 Nov 22. J Eur Acad Dermatol Venereol. 2018. PMID: 28960469

4

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.

Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, Ziv M, Pinter A, Vender R, Hugot S, You R, Milutinovic M, Thaçi D. Blauvelt A, et al. J Am Acad Dermatol. 2017 Jan;76(1):60-69.e9. doi: 10.1016/j.jaad.2016.08.008. Epub 2016 Sep 20. J Am Acad Dermatol. 2017. PMID: 27663079 Clinical Trial.

5

Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.

Ohtsuki M, Morita A, Igarashi A, Imafuku S, Tada Y, Fujita H, Fujishige A, Yamaguchi M, Teshima R, Tani Y, Nakagawa H. Ohtsuki M, et al. J Dermatol. 2017 Oct;44(10):1105-1111. doi: 10.1111/1346-8138.13911. Epub 2017 May 23. J Dermatol. 2017. PMID: 28543617 Free PMC article. Clinical Trial.

6

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).

Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, Mazur R, Patekar M, Charef P, Milutinovic M, Leonardi C, Mrowietz U. Bissonnette R, et al. J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507-1514. doi: 10.1111/jdv.14878. Epub 2018 Mar 22. J Eur Acad Dermatol Venereol. 2018. PMID: 29444376 Free PMC article. Clinical Trial.

7

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.

Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB. Papp KA, et al. Br J Dermatol. 2013 Feb;168(2):412-21. doi: 10.1111/bjd.12110. Epub 2013 Jan 18. Br J Dermatol. 2013. PMID: 23106107 Clinical Trial.

8

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.

Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M. Thaçi D, et al. J Am Acad Dermatol. 2015 Sep;73(3):400-9. doi: 10.1016/j.jaad.2015.05.013. Epub 2015 Jun 17. J Am Acad Dermatol. 2015. PMID: 26092291 Free article. Clinical Trial.

9

A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.

Ortiz-Salvador JM, Saneleuterio-Temporal M, Magdaleno-Tapial J, Velasco-Pastor M, Pujol-Marco C, Sahuquillo-Torralba A, Mateu-Puchades A, Pitarch-Bort G, Marí-Ruiz JI, Mataix-Díaz J, Montesinos-Villaescusa E, Miralles-Botella J, García-Fernández L, Martorell-Calatayud A, Belinchón-Romero I, Sánchez-Carazo JL, Pérez-Ferriols A. Ortiz-Salvador JM, et al. J Am Acad Dermatol. 2019 Aug;81(2):427-432. doi: 10.1016/j.jaad.2019.02.062. Epub 2019 Mar 11. J Am Acad Dermatol. 2019. PMID: 30872150 Free article.

10

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.

Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, Blauvelt A. Reich K, et al. Lancet. 2019 Sep 7;394(10201):831-839. doi: 10.1016/S0140-6736(19)31773-8. Epub 2019 Aug 8. Lancet. 2019. PMID: 31402114 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

373 results

Results by year